Recommended: How to Build Regulatory-Grade RWE Programs: A Practical Guide for Regulatory Affairs
Real-World Evidence: A Practical Guide for Regulatory Affairs TeamsReal-world evidence (RWE) has moved from a niche interest to a core component of regulatory strategy across markets.
When leveraged correctly, RWE can strengthen submissions, support label expansions, bolster safety monitoring, and inform lifecycle decisions.
This guide outlines pragmatic steps regulatory affairs teams can take to build credible RWE programs that align with regulatory expectations.
What is real-world evidence and why it matters
RWE is clinical evidence derived from real-world data (RWD) such as electronic health records, claims databases, registries, patient-reported outcomes, and remote monitoring. Regulators increasingly accept RWE to complement randomized controlled trials, particularly for post-market safety, rare disease populations, comparative effectiveness, and long-term outcomes. For regulatory affairs, RWE offers a path to faster insight, broader patient representation, and evidence that reflects routine clinical practice.
Core elements of a robust RWE strategy
– Clearly defined regulatory questions: Start with the decision the evidence must support — safety signal evaluation, label expansion, reimbursement, or comparative effectiveness.
A focused question guides study design and data choice.
– Fit-for-purpose data: Choose data sources that capture the endpoints and populations of interest. Consider data completeness, coding practices, representativeness, and linkage potential across datasets.
– Transparent study design: Pre-specify protocols, analytic plans, and sensitivity analyses. Use established methodologies to minimize bias (e.g., propensity scores, new-user designs, active comparators) and document assumptions.
– Data quality and governance: Implement data cleaning standards, provenance tracking, and reproducible pipelines. Maintain audit trails and version control for datasets and code to meet regulatory scrutiny.
– Cross-functional collaboration: Integrate clinical, epidemiology, biostatistics, safety, HTA, and legal teams early.
Alignment reduces rework and increases credibility with regulators and payers.
– Regulatory engagement: Seek early scientific advice or parallel consultations where available. Share protocols and analytic plans to obtain feedback and reduce downstream requests.
Practical considerations for implementation
– Use a targeted pilot approach: Start with a limited program tied to a specific regulatory question. Pilots help refine workflows, governance, and vendor relationships.
– Vendor and partner evaluation: Assess partners for experience with regulatory-grade RWE, data access arrangements, privacy compliance, and analytic transparency.
– Harmonize standards: Adopt common data models and standardized terminologies when possible to facilitate reproducibility and cross-database studies.
– Address privacy and consent: Ensure compliance with relevant data protection laws and document lawful basis for processing. Consider de-identification and secure environments for analysis.
Common pitfalls and how to avoid them
– Overreliance on convenience datasets: Not all accessible data are suitable for regulatory questions. Evaluate fit-for-purpose rigorously.
– Underestimating documentation needs: Regulators expect traceability of decisions, datasets, and code. Invest in reproducible workflows and documentation.
– Isolated teams: RWE programs succeed when regulatory strategy is integrated across functions from the outset.
Checklist to prepare for regulatory use of RWE
– Define regulatory objective and primary endpoints
– Map potential data sources and assess fit-for-purpose
– Draft protocol and statistical analysis plan early
– Set data governance, provenance, and documentation standards
– Engage regulators or seek scientific advice where feasible
– Pilot, iterate, and scale based on lessons learned
Well-designed RWE programs can accelerate decision-making and support robust regulatory interactions. When aligned with clear objectives, rigorous methods, and transparent documentation, RWE becomes a powerful tool for demonstrating real-world value and maintaining regulatory compliance across the product lifecycle.